Sarepta's gene therapy medicine kills patient, CEO suspends full year guidance

We've got a number of downgrades as you might expect of Serepta today. This after the death of a second patient who received the company's gene therapy to treat Duchaine's muscular drophy. Angelica Peebles is here.She has more on the story for us. Angelica. Morning David.That's right. Surf is saying a 15-year-old who received the company's gene therapy. It's called Elevus dying from liver failure.And this is the second instance in just a matter of months. The other patient was a 16-year-old boy. And both of ...